






**Supplementary Figure 1.** *The effects of endo- and exocannabinoids on HSC proliferation and apoptosis.* (A) LDH leakage after 48 h, (B) DNA synthesis (BrdU incorporation) and (C) caspase-3 and bax, measured by Western Blotting after 24 h treatment with 2-AG or THC alone, or in combination with AA (means  $\pm$  SD).



**Supplementary Figure 2.** *The effect of EtOH on HSC gene expression. CB1, PC $\alpha$ 1(I) and  $\alpha$ SMA mRNA expression, measured by TaqMan PCR and normalized to GAPDH. (means  $\pm$  SD).*



**Supplementary Table 1** Primers and probes used for TaqMan PCR

Target gene*	5'-Primer	Probe	3'-Primer
<b>CB1</b> (h)	TCCGCATGATTGAGCGTG	CCCAGAAGAGCATCATCATCACACG	ACCTGTACCTTCCCATCTCA
<b>CB1</b> (r)	GACTTCCATGTATTCCACCGTAAAG	CAGCCCCAATGTGTTTCTGTC	GGCTGTAACCCACCCAGTT
<b>CB2</b> (h)	CCGCCATTGACCGATACCT	TGCCTGCGCTATCCACCTTC	ACGGGTGAGCAGAGCTTTGT
<b>PC <math>\alpha</math>1(I)</b> (h)	CAGCCGCTTCACCTACAG	TGGCTGCACGAGTCACACCCGG	GGTTTTGTATTCAATCACTGTCTT
<b>PC <math>\alpha</math>1(I)</b> (m)	TCCGGCTCCTGCTCCTCTTA	TTCTTGGCCATGCGTCAGGAGGG	GTATGCAGCTGACTTCAGGGATGT
<b>PC <math>\alpha</math>1(I)</b> (r)	TCCGGCTCCTGCTCCTCTTA	TTCTTGGCCATGCGTCAGGAGGG	GTATGCAGCTGACTTCAGGGATGT
<b><math>\alpha</math>SMA</b> (r)	GCTGACAGGATGCAGAAGGA	CACCATGAAGATCAAGATTATTGCTCCTCCAG	GCCGATCCAGACAGAAATTTTG
<b><math>\alpha</math>SMA</b> (m)	ACAGCCCTCGCACCCCA	CAAGATCATTGCCCTCCAGAACGC	GCCACCGATCCAGACAGAGT
<b>TIMP-1</b> (m)	TCCTCTTGTTGCTATCCTGATAGCTT	TTCTGCAACTCGGACCTGGTCATAAGG	CGCTGGTATAAGGTGGTCTCGTT
<b>TIMP-1</b> (r)	TCCTCTTGTTGCTATCCTGATAGCTT	TTCTGCAACTCGGACCTGGTATAAGG	CGCTGGTATAAGGTGGTCTCGAT
<b>TGF<math>\beta</math>1</b> (m)	AGAGGTCACCCGCGTGCTAA	ACCGCAACAACGCCATCTATGAGAAAACCA	TCCCGAATGTCTGACGTATTGA
<b>TGF<math>\beta</math>1</b> (r)	AGAAGTCACCCGCGTGCTAA	ACCGCAACAACGCAATCTATGACAAAACCA	TCCCGAATGTCTGACGTATTGA
<b>MMP-3</b> (m)	GATGAACGATGGACAGAGGATG	TGGTACCAACCTATTCTGTGTTGCTGC	AGGGAGTGGCCAAGTTCATG
<b>MMP-2</b> (m)	CCGAGGACTATGACCGGGATAA	TCTGCCCGAGACCGCTATGTCCA	CTTGTTGCCAGGAAAGTGAAG
<b>MMP-13</b> (m)	GGAAGACCCTCTTCTCTCT	TCTGGTTAACATCATCATACTCCACACGT	TCATAGACAGCATCTACTTTGTT
<b>COX-2</b> (m)	CAAGCAGTGGCAAAGGCCT	CATTGACCAGAGCAGAGAGATGAAATACCAGTC	GCGTTTGCGGTACTCATTGA
<b>TNF<math>\alpha</math></b> (m)	GACCAGGCTGTGCTACATCA	TGAACCTCTGCTCCCCACGGGA	GTAGGGCGATTACAGTCAACGG
<b>iNOS</b> (m)	GGCAGCCTGTGAGACCTTTG	TGTCCGAAGCAAACATCACATTCAGATCC	TTGCATTGGAAGTGAAGCGTT
<b>GAPDH</b> (h)	CCAGGAAATGAGCTTGACAAAGTT	TCGTTGAGGGCAATGCCAGCC	CTCCTCCACCTTTGACCGCTG
<b>GAPDH</b> (r)	CTGCCAAGTATGATGACATCAAGAA	TCGGCCGCCTGCTTCACCA	AGCCCAGGATGCCCTTTAGT
<b>GAPDH</b> (m)	ACTGGCATGGCCTTCCG	TTCTACCCCCAATGTGTCCGTCGT	CAGGCGGCACGTCAGATC

**Abbreviations:**  $\alpha$ SMA – alpha smooth muscle actin; CB1/2 – cannabinoid receptors 1 and 2; COX-2 – cyclooxygenase-2; iNOS – inducible nitric oxide synthase; GAPDH -

glyceraldehyd-3-phosphat-dehydrogenase; MMP – matrix metalloproteinase; PC  $\alpha$ 1(I)  
– procollagen alpha 1(I); TIMP-1 – tissue inhibitor of matrix metalloproteinase-1; TGF $\beta$   
– transforming growth factor beta; TNF $\alpha$  – tumor necrosis factor alpha.

\*CTGF (connective tissue growth factor), PDGF (platelet derived growth factor) and  
MMP-9 - ready to use kits from Qiagen (Hilden, Germany) for which the sequences were  
not provided.